Should You Buy aTyr Pharma Inc (LIFE) Today? Analysis, Price Targets, and 2026 Outlook.
No data
Options Data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast LIFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIFE is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0
Wall Street analysts forecast LIFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIFE is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
0
Current: 19.000
Low
0
Averages
0
High
0
0
Current: 19.000
Low
0
Averages
0
High
0
KeyBanc
Steve Dechert
maintain
AI Analysis
2026-01-08
Reason
KeyBanc
Steve Dechert
Price Target
AI Analysis
2026-01-08
maintain
Reason
KeyBanc analyst Steve Dechert raised the firm's price target on LifeStance to $8.50 from $6.50 and keeps an Overweight rating on the shares. Coming off a choppy year for HCIT stocks, fundamentally, the firm did see a "year of inflection" for many of its names with estimate revisions plus valuations largely bottoming. While KeyBanc expects momentum to continue for most of its coverage, the firm does see valuation multiples impacted by competition concerns and regulatory impacts.
Citizens
Outperform -> Market Perform
downgrade
$NULL
2026-01-05
Reason
Citizens
Price Target
$NULL
2026-01-05
downgrade
Outperform -> Market Perform
Reason
Citizens downgraded Life360 to Market Perform from Outperform without a price target. The company's core growth has slowed recently, and Citizens is now "more skeptical" of its 2026 catalysts, the analyst tells investors in a research note. The firm says Life360 will lap a successful U.S. advertising campaign in 2026, while its U.S. price increases are also likely more limited until the company releases another major feature update.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LIFE
